Printer Friendly

BioAlliance Pharma Announces Positive Preliminary Pivotal Phase III Results in Herpes Labialis with Acyclovir Lauriad[R].

PARIS -- Regulatory News:

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, is pleased today to announce positive preliminary results in its LIP phase III pivotal study (Lauriad[R] Immunocompetent Patients Study ). This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad[R] 50mg Mucoadhesive Buccal Tablet (MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes.

In the acyclovir Lauriad[R] patient group among the 722 patients included, the duration of episode from the first prodromal symptoms to healing was significantly decreased (p= 0.0062). In addition, the percentage of patients with abortive lesions (without vesicular lesion) was increased (p=0.051) and among patients presenting primary vesicular lesions, the time to healing was reduced (p=0.058).

"These data show that acyclovir Lauriad[R] brings a strong clinical benefit to patients both in preventing and treating recurrent oro-facial herpes. This trial provides a good basis for a constructive dialog with the regulatory authorities. These results strongly validate the Mucoadhesive Buccal Tablet concept based on early targeted treatment", said Dominique Costantini, President and CEO of BioAlliance Pharma.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at


This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website ( or on BioAlliance Pharma S.A.'s website (
COPYRIGHT 2009 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 26, 2009
Previous Article:AMD Publishes Ninth Annual Global Climate Protection Plan and 2008 Corporate Responsibility Report.
Next Article:Amazon Web Services Announces Amazon Virtual Private Cloud -- Now Enterprises Can Seamlessly Connect Existing IT Infrastructures to AWS and Continue...

Related Articles
Micrologix enters into exclusive license negotiation period to partner MBI-226.
FDA grants ESP Pharma Orphan Drug status for IV Terlipressin for treating type 1 hepato-renal syndrome.
ViroPharma granted fast track status by FDA for CMV prevention drug candidate.
Par Pharmaceutical licenses United States commercialization rights to antifungal Loramyc.
Strativa provides update on development status of pafuramidine and other in-licensed products.
Melissa officinalis oil affects infectivity of enveloped herpesviruses.
Herpes drug does not cut HIV transmission risk.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters